KLRA insider transaction filings
Kailera Therapeutics, Inc. — 20 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-09. Screen KLRA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 2 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Nicholson Nur — Chief Technology Officer | 1 | — | — | 1 |
| Tregoning Kathleen — See Remarks | 1 | — | — | 1 |
Recent Form 4 filings — Kailera Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Nicholson Nur — Chief Technology Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Tregoning Kathleen — See Remarks | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Renaud Ronald C JR — CEO & President, Director | Option exercise (M): 38,094 @ $5.25 · Option exercise (M): 38,094 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. — 10% owner | Conversion (C): 9,477,719 · Conversion (C): 2,034,133 · Conversion (C): 4,968,789 (derivative) @ $0 · Conversion (C): 708,814 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | RTW INVESTMENTS, LP — 10% owner WONG RODERICK — 10% owner | Conversion (C): 10,276,820 · Purchase (P): 500,000 @ $16 · Conversion (C): 8,250,000 (derivative) · Conversion (C): 2,026,820 (derivative) | EDGAR |
| 2026-04-20 | 4 | Coleman Jamie Beth — Chief Commercial Officer | Grant/award (A): 75,000 (derivative) @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Wasserman Scott M. — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Akamine Scott — Chief Legal Officer | Grant/award (A): 60,000 (derivative) @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Hite Christopher — Director | Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Clyburn Frank — Director | Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Kaplan Andrew T. — Director, 10% owner | Conversion (C): 17,857,143 · Purchase (P): 8,398,438 @ $16 · Conversion (C): 17,857,143 (derivative) @ $0 · Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Cloghessy Paula — Chief People Officer | Grant/award (A): 60,000 (derivative) @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Burgess Paul D. — See Remarks | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Bain Capital Life Sciences Investors, LLC — 10% owner Bain Capital Life Sciences IV General Partner, LLC — 10% owner Bain Capital Life Sciences Fund IV, L.P. — 10% owner BCLS Fund IV Investments GP, LLC — 10% owner BCLS Fund IV Investments, L.P. — 10% owner | Conversion (C): 16,875,000 · Conversion (C): 4,145,768 · Purchase (P): 1,562,500 @ $16 · Conversion (C): 16,875,000 (derivative) @ $0 · Conversion (C): 4,145,768 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Pagan Douglas W. — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Koppel Adam — Director, 10% owner | Conversion (C): 16,875,000 · Conversion (C): 4,145,768 · Purchase (P): 1,562,500 @ $16 · Conversion (C): 16,875,000 (derivative) @ $0 · Conversion (C): 4,145,768 (derivative) @ $0 · Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | MACKAY MARTIN — Director | Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Renaud Ronald C JR — CEO & President, Director | Grant/award (A): 300,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | MILLIGAN JOHN F — Director | Grant/award (A): 38,300 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | BAIN CAPITAL INVESTORS LLC — 10% owner Bain Capital XIV General Partner, LLC — 10% owner Bain Capital Fund XIV, L.P. — 10% owner BCPE Perseus Investor GP, LLC — 10% owner BCPE Perseus Investor, LP — 10% owner | Conversion (C): 17,857,143 · Purchase (P): 8,398,438 @ $16 · Conversion (C): 17,857,143 (derivative) @ $0 | EDGAR |
Recent 8-K events — Kailera Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KLRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →